Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.

Expert opinion on drug safety - 1 Oct 2014

Davidson Brittany Anne, Moorman Patricia G

Abstract excerpt

INTRODUCTION: Oral contraceptive pills (OCPs) are the most frequently used form of effective, reversible contraception among women of childbearing potential. In the average risk population, OCPs may offer a protective benefit against ovarian, endometrial and colorectal malignancies. In women at high risk for breast, ovarian, endometrial or colorectal malignancies, the risk-benefit profile is less well studied....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Breast Neoplasms
Share to Colorectal Neoplasms, Hereditary Nonpolyposis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 gene

Share to Genetic Predisposition to Disease

Share to Genital Neoplasms, Female

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 25146351
DOI: 10.1517/14740338.2014.951327

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.PMID 25146351Read ↗

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.Semantic proximity Read ↗

Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.Semantic proximity Read ↗

Screening and prevention of hereditary gynecologic cancers.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.Semantic proximity Read ↗

Management options after prophylactic surgeries in women with BRCA mutations: a review.Semantic proximity Read ↗

Cancer Risk-Reducing Opportunities in Gynecologic Surgery.Semantic proximity Read ↗

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.Semantic proximity Read ↗

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.Semantic proximity Read ↗

Oral contraceptives and family history of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.